MacIntyre C, Das A, Chen X, de Silva C, Doolan C
Viruses. 2020; 12(1).
PMID: 31892158
PMC: 7019718.
DOI: 10.3390/v12010033.
Perry M, Warren R, Merchlinsky M, Houchens C, Rogers J
Front Cell Infect Microbiol. 2018; 8:356.
PMID: 30345258
PMC: 6182097.
DOI: 10.3389/fcimb.2018.00356.
Schmitt A, Gan L, Abd El Wahed A, Shi T, Ellerbrok H, Kaup F
Viruses. 2017; 9(12).
PMID: 29182537
PMC: 5744138.
DOI: 10.3390/v9120363.
Keckler M, Reynolds M, Damon I, Karem K
Vaccine. 2013; 31(45):5192-201.
PMID: 23994378
PMC: 4623313.
DOI: 10.1016/j.vaccine.2013.08.039.
Milton D
Front Cell Infect Microbiol. 2012; 2:150.
PMID: 23226686
PMC: 3509329.
DOI: 10.3389/fcimb.2012.00150.
Susceptibility of monkeypox virus aerosol suspensions in a rotating chamber.
Verreault D, Killeen S, Redmann R, Roy C
J Virol Methods. 2012; 187(2):333-7.
PMID: 23142251
PMC: 3556235.
DOI: 10.1016/j.jviromet.2012.10.009.
Comparative pathology of smallpox and monkeypox in man and macaques.
Cann J, Jahrling P, Hensley L, Wahl-Jensen V
J Comp Pathol. 2012; 148(1):6-21.
PMID: 22884034
PMC: 3498598.
DOI: 10.1016/j.jcpa.2012.06.007.
Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S, Chen N, Foster S, Hartzler H, Hembrador E, Hruby D
Antiviral Res. 2012; 94(1):44-53.
PMID: 22381921
PMC: 3722602.
DOI: 10.1016/j.antiviral.2012.02.005.
Evaluation of inhaled cidofovir as postexposure prophylactic in an aerosol rabbitpox model.
Verreault D, Sivasubramani S, Talton J, Doyle L, Reddy J, Killeen S
Antiviral Res. 2011; 93(1):204-8.
PMID: 22146565
PMC: 3505885.
DOI: 10.1016/j.antiviral.2011.11.013.
Development of ST-246® for Treatment of Poxvirus Infections.
Jordan R, Leeds J, Tyavanagimatt S, Hruby D
Viruses. 2011; 2(11):2409-2435.
PMID: 21994624
PMC: 3185582.
DOI: 10.3390/v2112409.
Development of CMX001 for the Treatment of Poxvirus Infections.
Lanier R, Trost L, Tippin T, Lampert B, Robertson A, Foster S
Viruses. 2011; 2(12):2740-2762.
PMID: 21499452
PMC: 3077800.
DOI: 10.3390/v2122740.
Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Rice A, Adams M, Wallace G, Burrage A, Lindsey S, Smith A
Viruses. 2011; 3(1):47-62.
PMID: 21373379
PMC: 3046869.
DOI: 10.3390/v3010047.
Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Rice A, Adams M, Lampert B, Foster S, Robertson A, Painter G
Viruses. 2011; 3(2):63-82.
PMID: 21369346
PMC: 3045966.
DOI: 10.3390/v3020063.
Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents.
Roy C, Voss T
Viruses. 2010; 2(9):2096-2107.
PMID: 20953322
PMC: 2954426.
DOI: 10.3390/v2092096.
Therapeutic and prophylactic drugs to treat orthopoxvirus infections.
Parker S, Handley L, Buller R
Future Virol. 2009; 3(6):595-612.
PMID: 19727418
PMC: 2600508.
DOI: 10.2217/17460794.3.6.595.
Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
Parker S, Schriewer J, Oberle C, Robertson A, Lanier R, Painter G
Antivir Ther. 2008; 13(7):863-73.
PMID: 19043920
PMC: 3730537.
Methods for sampling of airborne viruses.
Verreault D, Moineau S, Duchaine C
Microbiol Mol Biol Rev. 2008; 72(3):413-44.
PMID: 18772283
PMC: 2546863.
DOI: 10.1128/MMBR.00002-08.
Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox.
Adams M, Rice A, Moyer R
J Virol. 2007; 81(20):11084-95.
PMID: 17686856
PMC: 2045566.
DOI: 10.1128/JVI.00423-07.
Smallpox antiviral drug development: satisfying the animal efficacy rule.
Jordan R, Hruby D
Expert Rev Anti Infect Ther. 2006; 4(2):277-89.
PMID: 16597208
PMC: 9709928.
DOI: 10.1586/14787210.4.2.277.
Toward understanding the risk of secondary airborne infection: emission of respirable pathogens.
Nicas M, Nazaroff W, Hubbard A
J Occup Environ Hyg. 2005; 2(3):143-54.
PMID: 15764538
PMC: 7196697.
DOI: 10.1080/15459620590918466.